Who
Daniel Abdun-Nabi
Director
Company insider
Files Form 4 as: Board of Directors, Aptevo Therapeutics; Director, Regenxbio; CEO, Emergent BioSolutions.
In numbers
- Trades disclosed
- 278
- Buys
- 3
- Sells
- 48
- Bought
- $39K
- Sold
- $23.7M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 20 Nov 2006
- Last trade
- 6 Aug 2026
- Last filed
- 10 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Aug 2026filed 10 Aug 2026 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —400 | filing |
| 6 Aug 2026filed 10 Aug 2026 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —400 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —400 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —400 | filing |
| 6 Aug 2025filed 8 Aug 2025 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,200 at $0.00 | filing |
| 17 Jul 2025filed 21 Jul 2025 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1 at $0.00 | filing |
| 17 Jul 2025filed 21 Jul 2025 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —1 | filing |
| 17 Jul 2024filed 19 Jul 2024 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —925 at $0.00 | filing |
| 2 Jun 2024filed 3 Jun 2024 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —81 at $0.00 | filing |
| 2 Jun 2024filed 3 Jun 2024 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —81 | filing |
| 1 Jun 2024filed 3 Jun 2024 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7 at $0.00 | filing |
| 1 Jun 2024filed 3 Jun 2024 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —7 | filing |
| 9 Aug 2023filed 10 Aug 2023 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,571 at $0.00 | filing |
| 9 Aug 2023filed 10 Aug 2023 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,571 | filing |
| 2 Jun 2023filed 2 Jun 2023 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,571 at $0.00 | filing |
| 1 Jun 2023filed 2 Jun 2023 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —297 at $0.00 | filing |
| 1 Jun 2023filed 2 Jun 2023 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —297 | filing |
| 9 Aug 2022filed 10 Aug 2022 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,571 at $0.00 | filing |
| 1 Jun 2022filed 3 Jun 2022 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —298 at $0.00 | filing |
| 1 Jun 2022filed 3 Jun 2022 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —298 | filing |
News
Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)EBS · tickerreport.com · 16 Oct 2026Aptevo Therapeutics: Aptevo to Showcase Multispecific Platform at SITC 2026 Annual MeetingAPVO · finanznachrichten.de · 14 Oct 2026
0 headlines in the last 90 days name Daniel Abdun-Nabi; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.